Podcasts about biofourmis

William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Akshay Suvas Desai, MD, MPH of Brigham and Women's Hospital, and Sunil Kapur, MD of Brigham and Women`s Hospital to discuss how the Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT) showed a greater benefit with respect to mortality at 5 years among patients who received cardiac-resynchronization therapy (CRT) than among those who received implantable cardioverter–defibrillators (ICDs). However, the effect of CRT on long-term survival is not known. We randomly assigned patients with New York Heart Association (NYHA) class II or III heart failure, a left ventricular ejection fraction of 30% or less, and an intrinsic QRS duration of 120 msec or more (or a paced QRS duration of 200 msec or more) to receive either an ICD alone or a CRT defibrillator (CRT-D). We assessed long-term outcomes among patients at the eight highest-enrolling participating sites. The primary outcome was death from any cause; the secondary outcome was a composite of death from any cause, heart transplantation, or implantation of a ventricular assist device.  https://www.hrsonline.org/education/TheLead https://www.nejm.org/doi/full/10.1056/NEJMoa2304542 Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research: Medtronic Contributor Disclosure(s): A. Suvas Desai: Honoraria/Speaking/Consulting: Abbott, Novartis, AstraZeneca, BioFourmis, Regeneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlaxoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal, Research: Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Novartis  S. Kapur: Honoraria/Speaking/Consulting: Medtronic, Novartis, Abbott, Biotronik This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode53

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, February 27, 2024. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. Owlet is set to raise $9 million to support its infant monitoring technology. Fast Five hosts Danielle Kirsh and Sean Whooley talk about the technology and some of the terms of the funding. GE HealthCare and Biofourmis are collaborating on at-home patient monitoring. Hear more about the goal of the partnership and how it will help patients. Irish startup Gasgon Medical is looking to raise €4 million for its IV delivery technology. Whooley explains the company's technology and what some of the funding will support. Virtual Incision won an FDA nod for its miniature MIRA surgical robot for use in colectomies. The Fast Five hosts discuss what the robot does and the pathway Virtual Incision took to get to this point. Integra Lifesciences has announced it is closing one of its plants. Learn about which plant is closing and how many people it affects.

Shiyan Koh, Managing Partner of Hustle Fund, and I talked about three main topics: 1. Layoffs and Market Exits: Shiyan and I talked about the recent wave of layoffs: Biofourmis (45 staff in Singapore, and at least 85 staff globally) and Flash Coffee (closed all 11 Singapore outlets). We agreed on the importance of executing layoffs decisively, advocating for a single, well-planned and deep cut rather than a drawn-out process of multiple cuts. We touched upon the necessity of transparent communication, ensuring that the remaining team members are well-informed and supported throughout the transition, and highlighted the importance of agility in uncertain times. 2. Tech-Enabled D2C Consumer: We explored tech-enabled food services and analyzed the industry's financial intricacies, distribution challenges, and competitive landscape. We debated how coffee chains utilize tech not only in processing orders, how they choose locations, and differentiate in markets already saturated with traditional coffee chains. We talked about Luckin Coffee's unique model, which requires customers to download an app before placing an order, a strategy that streamlines the ordering process and serves customer acquisition and data collection, allowing it to better tailor its offerings and marketing strategies. 3. AI Productivity Transformation: We discussed EU's aim for AI regulations, similar to its GDPR for data privacy, vs. ASEAN's recently-stated hands-off approach, letting each country decide its own path. We also discussed the difficulty of halting AI development and pointed out the practical issues of enforcing regulations. We were skeptical about JPMorgan CEO Jamie Dimon's forecast of a 3.5 day workweek due to AI. While AI enhances productivity, it also intensifies competition, ultimately transforming entire industries rather than individual jobs. We also talked about AI bots and how they can already emulate the conversational style of specific individuals like Jason Calacanis and brainstormed possibilities like historical fiction podcasts featuring debates between figures like Napoleon and Gandhi. We also touched upon the NASDAQ performance of the MoneyHero SPAC (Seedly), authenticity and value of human error and spontaneity in content creation, suggesting that there might still be a preference for “artisanal podcasters”, the necessity of continuous learning and adaptation, the ethical dimensions of AI deployment, fostering innovation while ensuring data privacy and the strategies for maintaining balance and humanity in the fast-paced tech world. Watch, listen or read the full insight at https://www.bravesea.com/blog/flash-coffee-layoffs Get transcripts, startup resources & community discussions at www.bravesea.com WhatsApp: https://chat.whatsapp.com/CeL3ywi7yOWFd8HTo6yzde Spotify: https://open.spotify.com/show/4TnqkaWpTT181lMA8xNu0T YouTube: https://www.youtube.com/@JeremyAu Apple Podcasts: https://podcasts.apple.com/sg/podcast/brave-southeast-asia-tech-singapore-indonesia-vietnam/id1506890464 Google Podcasts: https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkLnBvZC5jby9icmF2ZWR5bmFtaWNz TikTok: https://www.tiktok.com/@jeremyau Instagram: https://www.instagram.com/jeremyauz Twitter: https://twitter.com/jeremyau LinkedIn: https://www.linkedin.com/company/bravesea Learn more about Ringkas here: https://www.ringkas.co.id

Command Centers aren't just for Tom Clancy enthusiasts anymore. Rip off your scrubs, or don't, and head to the situation room as Elliott and Sarah virtual nursing as a strategic imperative for health system survival and thrival (?!) with Sarah Bell, Vice President of Customer Success and Clinical Implementation at Biofourmis. Plus! Sarah and Elliott go tete-a-tete in a new G.A.M.E. that rivals Techpocalypse Now (Episode 1.02). Don't go chasing waterfalls, it's time to Tech It to the Limit! Original music by: Evan O'Donovan Additional music by: Vitaliy Levkin and RomanSenykMusic from Pixabay

William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by Kolade Muchaili Agboola, MD, and Akshay Suvas Desai, MD, MPH, of Brigham and Women's Hospital to discuss the results and implications of the CASTLE-HTx trial.   https://www.hrsonline.org/education/TheLead   Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic   Contributor Disclosure(s): K. Agboola: No relevant financial relationships with ineligible companies to disclose.  A. Desai: Honoraria/Speaking/Consulting Fee: Abbott, Novartis, AstraZeneca, BioFourmis, Regeneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlaxoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal; Research (Contracted Grants for PIs Named Investigators Only): Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Novartis

June 21 Today on the Conference channel, it's an Interview in Action live from HIMSS 2023 with Tahir Haque, MD, Senior Medical Director at Biofourmis. What are the four main components of delivering successful care in the home? What challenges do health systems face when trying to push care outside of their four walls? How does Bioformis adapt its solutions to cater to the specific requirements of each community, and what role does technology play in enabling equitable care at home?"The Patient Experience - A Technology Perspective" is a live webinar that explores the intersection of healthcare and technology, focusing on enhancing the patient experience. As healthcare systems prioritize patient-centered care, leveraging technology becomes crucial. Join us on July 6th, 1:00 PM ET and join the discussion! Register Here. - https://thisweekhealth.com/leader-series-the-patient-experience-a-technology-perspective/Subscribe: This Week HealthTwitter: This Week HealthLinkedIn: Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Technology plays a heavy role in driving equitable care delivery. In this episode, Dr. Maulik Majmudar, shares about his company's platform, which enables health systems and provider groups to scale their programs at the patients' homes. Even before the COVID pandemic, the transition of care out of the brick-and-mortar sites into patients' homes was starting, but many health systems still lack the technology and the teams to support this successfully. Dr. Majmudar explains how the Biofourmis platform can manage patients' care remotely and uses digital tools that can drive better outcomes. Tune in to learn how the Biofourmis platform is making waves in remote patient management and health equity!

Episode Re-Release. Alex Merwin hosts a group of health innovation leaders from startups, investors, media and startup enabling organizations for a special HLTH compilation episode. We asked each innovator two questions: what is special about convening in-person at events in this post-covid world, and if they could wave a magic wand to eliminate any hurdle to health innovation what would they change and why. Thanks to our guests from Redesign Health, Maven Clinic, Luma Health, Health Gorilla, Matter, Mission Based Media, Keep Labs, Memora Health, Unseen Capital, BioFourmis, and Brightside Health. Learn more about how AWS enables healthcare & life sciences startups to grow and thrive at https://aws.amazon.com/startups/ and https://aws.amazon.com/health/.

About Maulik Majmudar:Dr. Maulik Majmudar is the co-founder and Chief Medical Officer at Biofourmis. Dr. Majmudar served as Medical Officer at Amazon, where he led several healthcare-related initiatives. Before Amazon, Dr. Majmudar was associate director of the Healthcare Transformation Lab at Massachusetts General Hospital and an assistant professor at Harvard Medical School, where he was responsible for the identification, validation, and implementation of digital health solutions to improve care delivery. Things You'll Learn:Someone's location should not be a factor that makes a big difference in healthcare outcomes.The Biofourmis platform is a disease, site of care, and acuity agnosticRemote Patient Management means that the data collected remotely is used for monitoring but also handled, interpreted, and executed.In healthcare, the ultimate measures of success are outcomes and unit economics.Obesity, high blood pressure, and diabetes are prevalent in socioeconomically deprived neighborhoods and underserved populations with little to no access to care. Resources:Connect with and follow Maulik Majmudar on LinkedIn.Follow Biofourmis on LinkedIn.Discover the Biofourmis Website.

Tune in for today's industry updates.

Alex Merwin hosts a group of health innovation leaders from startups, investors, media and startup enabling organizations for a special HLTH compilation episode. We asked each innovator two questions: what is special about convening in-person at events in this post-covid world, and if they could wave a magic wand to eliminate any hurdle to health innovation what would they change and why. Thanks to our guests from Redesign Health, Maven Clinic, Luma Health, Health Gorilla, Matter, Mission Based Media, Keep Labs, Memora Health, Unseen Capital, BioFourmis, and Brightside Health. Learn more about how AWS enables healthcare & life sciences startups to grow and thrive at https://aws.amazon.com/startups/ and https://aws.amazon.com/health/.

In this month's Digital Health Roundup, Medtech Insight's Marion Webb provides highlights from the recent HLTH conference in Las Vegas. Reed Miller and Barnaby Pickering offer an overview of the highly competitive diabetes tech market. We also talk about digital health in Germany and Europe. Medtech Insight articles addressing topics discussed in this episode: HLTH Conference Promises Festival Vibe On One Big Stage; Health Equity, Women's Health, Digital Health https://medtech.pharmaintelligence.informa.com/MT146035/HLTH-Conference-Promises-Festival-Vibe-On-One-Big-Stage-Health-Equity-Womens-Health-Digital-Health HLTH 2022 Roundup: Mirvie, Grail, Biofourmis, Komodo Health, Babson Diagnostics https://medtech.pharmaintelligence.informa.com/MT146060/HLTH-2022-Roundup-Mirvie-Grail-Biofourmis-Komodo-Health-Babson-Diagnostics HLTH 2022 Roundup: CEOs Of BD And Google Cloud On Innovation, Interoperability, AI https://medtech.pharmaintelligence.informa.com/MT147361/HLTH-2022-Roundup-CEOs-Of-BD-And-Google-Cloud-On-Innovation-Interoperability-AI Medtech Monthly, Ep. 4: The Future Of Diabetes Tech https://medtech.pharmaintelligence.informa.com/MT146000/Medtech-Monthly-Ep-4-The-Future-Of-Diabetes-Tech

What if there was a way to change the trajectory of human health? Our era is marked by the proliferation of inexpensive, but high quality IoT sensors that enable advanced early disease detection. A way to measure human physiology in a continuous manner. That's exactly what data sciences company Biofourmis is doing. CTO, Milan Shah explains how the combination of IoT, artificial intelligence, and machine learning is enabling clinicians to interpret patient's biometric data and identify earlier warnings than ever before. This allows clinicians to intervene earlier, improve patients' quality of life, and provide them with better outcomes. Join us as we discuss: · How Biofourmis is identifying physiological deterioration using ML and AI algorithms · The types of medical-grade IoT sensors in the market today · The power and potential of biomarkers · How the COVID-19 outbreak was managed in Singapore with Biofourmis' solution · Why personalised predictive healthcare is the future Show Links · Check out Biofourmis · Follow Milah Shah on LinkedIn · Connect with Eseye on LinkedIn or Twitter

How can we transform patient health through personal and predictive care?By taking it home.Sheeza Hussain is the Chief Commercial Officer of Biofourmis, a global leader in digital therapeutics. Biofourmis has a vision to improve the delivery of healthcare by treating patients with chronic and acute medical conditions outside of the hospital utilizing advanced technology.On this episode, Sheeza joins hosts Dr. Gautam Gulati, Dr. Jessica Shepherd, and Dr. Jordan Shlain to discuss how Biofourmis is using continuous vitals monitoring to prevent adverse events before they happen, allowing patients to get healthy at home.Listen as Sheeza shares Biofourmis' mission to expand AI into people's  lives by creating innovations that meet patients at home. Scientific studies support the fact that patients recover more comfortably in their own environment and now technology is making it possible for aging to happen at home.Topics CoveredHow Biofourmis is like the OnStar for your healthAn inside look at the data and the analytics of Biofourmis' bio vitals indexThe 3 tools the Biofourmis platform uses to customize careThe partnerships required for hospital-at-home patient selectionSheeza's passion for the future and how demand is increasing for patients to receive their care at homeConnect with Sheeza HussainSheeza Hussain on LinkedInConnect with Dr. Gautam Gulati, Dr. Jordan Shlain, & Dr. Jessica ShepherdDr. Gulati on TwitterDr. Gulati on LinkedInDr. Shlain on TwitterDr. Shlain on LinkedInDr. Shepherd on LinkedInDr. Shepherd on TwitterResourcesBiofourmisViVE

Sheeza Hussain, chief commercial officer for remote patient monitoring firm Biofourmis, discusses commercial strategies in digital medicine during what's been a relatively quiet investment period for health tech. Follow us on twitter: @MMMnews www.mmm-online.com

Laura Dyrda gives updates on the Digital Health + Health IT industry.

Biofourmis is not your typical standalone DTx company! On the heels of a $300M round, Biofourmis has evolved to a full data driven healthcare services organization with a strong foundation of digital therapies driving care decisions. To learn more about their work and plans for the future, I went straight to Kuldeep Singh Rajput, founder and CEO of Biofourmis. Biofourmis, in their own words, “utilizes machine learning, integrated technology and an FDA-cleared analytics engine to streamline connections between patients and care teams, leading to better outcomes for all.” In this episode we cover: The path from creation to funding Digital therapeutic companies evolving into virtual care platforms Kuldeep's business hypothesis to entrepreneurial journey Being device agnostic: build vs buy Patient adoption and utilization And much more! Guest Links and Resources: Connect with Kuldeep Singh on LinkedIn | Twitter Visit biofourmis.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Today, I welcome Dr. Maulik Majmudar, a cardiologist, Chief Medical Officer, and Co-Founder at Biofourmis, a rapidly growing virtual care delivery and digital therapeutics company. He dropped by the studio to bond over fathering boy/girl twins like me and to dive further down the rabbit hole of the modern-day train wreck that is America's fabulous healthcare system. Before his current position, Maulik was Medical Officer for a small, relatively unknown company named Amazon, where he led the development and launch of Amazon's first health membership service. As an Assistant Professor at Harvard Medical School, he was responsible for the identification, validation, and implementation of digital health solutions to improve care delivery and the patient and provider experience. That sounds like mumbo-jumbo, but we really do get into what this means in our conversation. Follow Maulik on Twitter @mdmajmudar and enjoy the show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

During the pandemic, many health systems piloted hospital at home and remote patient monitoring programs. As more and more providers and patients have experienced the benefits of receiving advanced care in the comfort of their homes, adoption has continued to grow. And with additional studies demonstrating lower cost and improved outcomes, more healthcare executives are accelerating their efforts to deliver care into the home. Leaders at academic medical centers are using their experience to evolve and improve their respective care at home programs. In this new episode of Healthcare Insider, Dr. Tahir Haque, medical director at Biofourmis, and Khurram Mir, senior manager at the University of California Irving Health, discuss how their organizations are leveraging virtual care innovations and share their thoughts on the future of delivering advanced care in the home. 

Whether used as a standalone therapy or in conjunction with prescribed medicine and medical devices, digital therapeutics are standing on the precipice of mainstream adoption. Companies like Omada Health and Biofourmis have already reached unicorn status, and that's just the beginning as DTx companies continue to secure record-breaking funding rounds. So on this episode of Shine, we've gathered three experts to discuss what you need to know about DTx. They share different perspectives from MedTech, payers, providers, and pharma, explore business models and reimbursement strategies, drive impactful behavior change, and more. Like so many things in life, the future of healthcare is digital. Listen now to find out why.

In this week's episode of Health Tech Deals, everyone cheats on each other: Eugene Borukhovich is the guest host replacing Jess! Eugene is cheating on Jim Joyce, while Matthew cheat on Jess; though Jess has cheated on me with Eugene before! Jess is on a cult retreat in Costa Rica, but Eugene and I have some deals to discuss: Biofourmis raises $300 million; Reify Health raises $220 million; Nex Health raises $125 million; and Amae Health raises “several million.”

We talk about how digital health including #GutTok, a trending gut health hashtag on Tik Tok, Biofourmis, and healthcare systems expanding to malls. We're drinking Billings Farm Cabernet Sauvignon! Check us out on Instagram or Tik Tok Music: Jaze Beats

In this week's episode of Health Tech Deals, everyone cheats on each other: Eugene Borukhovich is the guest host replacing Jess! Eugene is cheating on Jim Joyce, while Matthew cheat on Jess; though Jess has cheated on me with Eugene before! Jess is on a cult retreat in Costa Rica, but Eugene and I have some deals to discuss: Biofourmis raises $300 million; Reify Health raises $220 million; Nex Health raises $125 million; and Amae Health raises “several million.”

Calvin Chu Yee Ming is Managing Partner of Eden Strategy Institute, an award-winning strategy consulting firm that specializes in social innovation. Over the past decade, Eden has advised corporations like Bell Labs, General Electric, and Samsung; multilateral organizations such as UNDP, UNESCO, and UN Women; as well as governments in Singapore, New Zealand, and Saudi Arabia co-create sustainable value propositions, develop strategic roadmaps, and assess the impact of their interventions. Passionate about the interplay between businesses objectives and societal impact, Calvin is also Associate Lecturer in Strategy and Organization with the Royal Melbourne Institute of Technology. He has served on the boards of Biofourmis, Conjunct Consulting, Credence Labs, Rotary Club, the World Toilet Organisation, and as President of the Chicago Booth Alumni Club of Singapore. He was inducted into the International Who's Who of Professionals in 2009 and recognised as a NetImpact Changemaker in 2014. Most of his free time these days is spent exploring nature trails with his two young children. Show notes at: https://www.jeremyau.com/blog/calvin-chu You can find the community discussion for this episode at: https://club.jeremyau.com/c/podcasts/calvin-chu

The COVID-19 pandemic hit the gas pedal on the use of virtual care, particularly synchronous video chats. But virtual care's potential extends beyond one-on-one conversations – it can also leverage remote patient monitoring technology to take services out of the brick-and-mortar facility.Joining Healthcare IT News Senior Editor Kat Jercich to talk about telehealth's capabilities now and in the future is Dr. Maulik Majmudar, chief medical officer at Biofourmis.Talking points:The transition of care to "virtual-first"The evolution of the definition of telemedicineThe use cases of telehealth beyond synchronous video callsUsing acute-level hospital services as inspirationLooking at different disease processesCan technology drive equity?Algorithms assisting clinicians in making decisionsEvidence for telehealth's longevityEnsuring that patients are receiving appropriate careHow virtual care can be a tool rather than a hurdle for cliniciansConsolidation and integration will drive adoptionMore about this episode:Telehealth's post-COVID challenge: Integrating in-person careHow health systems should be preparing now for the future of hospital at homeHospital at home: How healthcare orgs can set programs up for successNurse unions slam Kaiser's advanced care at home strategyMayo Clinic, Kaiser put $100M toward hospital-at-home care

Sheeza Hussain is the Chief Commercial Officer of Biofourmis which is developing a hospital-at-home model for health systems that is even more in demand due to the stress of COVID-19 patients.  In addition to acute care, Biofourmis is also applying its remote monitoring technology to post-acute and chronic care. Sheeza explains, "When we think about hospital-at-home, we think about acute level type care-at-home. It's not about being cared for exactly as you would be in a hospital. But it's for those patients who still, for all intents and purposes, need to be monitored and need to be admitted to a hospital. But instead, they get to go home. They get monitoring equipment, they get to go to the comfort of their own bed, and they're still visited by clinicians or physicians every day in person as is a requirement for some of the reimbursement." "So when it comes to hospital-at-home, it's about in our case, a patch and we're device agnostic. We offer a patch that the patient wears on their chest, and it is continuously capturing data, things like the single-lead ECG, heart rate, respiratory rate. And that is feeding our analytics engine and allowing us to be able to establish a personalized baseline for each and every patient." @Biofourmis #HospitalatHome #RemoteCare #CareatHome #PatientMonitoring #PostAcute #ChronicCare #Hospitals Biofourmis.com Listen to the podcast here

Sheeza Hussain is the Chief Commercial Officer of Biofourmis which is developing a hospital-at-home model for health systems that is even more in demand due to the stress of COVID-19 patients.  In addition to acute care, Biofourmis is also applying its remote monitoring technology to post-acute and chronic care. Sheeza explains, "When we think about hospital-at-home, we think about acute level type care-at-home. It's not about being cared for exactly as you would be in a hospital. But it's for those patients who still, for all intents and purposes, need to be monitored and need to be admitted to a hospital. But instead, they get to go home. They get monitoring equipment, they get to go to the comfort of their own bed, and they're still visited by clinicians or physicians every day in person as is a requirement for some of the reimbursement." "So when it comes to hospital-at-home, it's about in our case, a patch and we're device agnostic. We offer a patch that the patient wears on their chest, and it is continuously capturing data, things like the single-lead ECG, heart rate, respiratory rate. And that is feeding our analytics engine and allowing us to be able to establish a personalized baseline for each and every patient." @Biofourmis #HospitalatHome #RemoteCare #CareatHome #PatientMonitoring #PostAcute #ChronicCare #Hospitals Biofourmis.com Download the transcript here

Neuroglee Therapeutics, a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. The funding will be used to launch virtual neurology clinics and to support Neuroglee's move to Boston. Other participants included Ramen Singh, the former chief executive officer of Mundipharma; Biofourmis […]

Anvesh is a Managing Director at MassMutual Ventures (MMV) and co-heads MMV's investment efforts in Asia. Prior to MMV, Anvesh was a Director and Head of Investments at Openspace Ventures, where he was part of the founding team. He started his career at Citi in the TMT Investment Banking team, during which he spent around 8 years in Hong Kong and Mumbai on M&A and financial advisory work with clients in the APAC region. Anvesh holds a BE in electronics and communications engineering from Anna University and an MBA from T.A. Pai Management Institute.Anvesh currently serves as a Director on the Boards of Biofourmis, Lynk, See-Mode, Milieu Insight and Qapita.In this episode, we will cover:1. Has the second wave of Covid in India impacted MMV's investment thesis? (2:00)2. Learnings from interactions with portfolio founders during covid (3:50)3. The rise of the enterprise tech ecosystem in Asia (8:00)4. Leaving investment banking for venture capital, what did the landscape look like back then vs where it is now (14:37)5. What is it like looking into different South East Asian marketing from a VC lens? (17:49)6. How do VCs help frame regulatory structures in frontier markets? (24:01)7. What does the LP appetite for Asia today look like? (28:54)8. Where and how does the the fund fit into MassMutual's macro ambitions? (32:10)9. What could the future thesis for MMV look like? (37:18)10. How does MMV look at the healthcare landscape across SEA? (44:04)11. Which is a better bet – a startup in a developing or establish market? (50:05)12 Role of regulatory framework in fostering customer loyalty (53:09)13. Evaluating similar business models across multiple geographies (56:45)14. What startups don't understand about SEA markets (58:39)

It's Health in 2 Point 00's 150th Episode or Sesquicentennial anniversary! On this episode, we have the return of Softbank money—$100M goes to Biofourmis platform for AI & Clinical Trials. Next, Amwell prices their IPO at $14-16 a share, and Grand Rounds raises $175 million led by the Carlyle Group. Finally, we have real foul play to report – former Zocdoc CEO Cyrus Massoumi filed a lawsuit accusing his fellow cofounders and CFO of foul play, so Jess asks me to dish the dirty details.

On Episode 117, we bring you the late-night edition of Health in 2 Point 00. Jess asks me about Wellthy Therapeutics raising $4 million—they're a digital therapeutics company I've been working with out of the Bayer group, definitely a space to watch. Lionrock Recovery raises $7 million, lots of activity in this area of telehealth for recovery and rehabilitation. Also getting $7 million is Datos Health, an Israeli company with a remote monitoring platform. Finally, Biofourmis acquired Gaido Health, expanding into the oncology space. —Matthew Holt